Wells Fargo & Company MN Has $2.04 Million Stake in Arcellx, Inc. (NASDAQ:ACLX)

Wells Fargo & Company MN increased its position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 35.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,638 shares of the company's stock after acquiring an additional 7,002 shares during the period. Wells Fargo & Company MN's holdings in Arcellx were worth $2,043,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Headlands Technologies LLC bought a new stake in shares of Arcellx in the 4th quarter valued at approximately $41,000. KBC Group NV grew its position in Arcellx by 37.3% in the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after acquiring an additional 377 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Arcellx during the 4th quarter valued at $184,000. Kazazian Asset Management LLC acquired a new stake in shares of Arcellx in the 4th quarter valued at $204,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Arcellx in the fourth quarter worth $214,000. Hedge funds and other institutional investors own 96.03% of the company's stock.

Insider Transactions at Arcellx

In related news, insider Rami Elghandour sold 38,300 shares of the business's stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the completion of the transaction, the insider now owns 149,186 shares of the company's stock, valued at approximately $9,252,515.72. The trade was a 20.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total value of $96,855.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 55,955 shares of company stock worth $3,504,758. 6.24% of the stock is owned by insiders.

Arcellx Trading Up 0.2 %

NASDAQ ACLX traded up $0.15 during trading on Thursday, hitting $65.10. 45,012 shares of the company traded hands, compared to its average volume of 552,516. Arcellx, Inc. has a 12 month low of $47.88 and a 12 month high of $107.37. The business has a fifty day simple moving average of $64.77 and a 200 day simple moving average of $74.43. The company has a market capitalization of $3.58 billion, a P/E ratio of -91.44 and a beta of 0.33.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). The company had revenue of $15.27 million during the quarter, compared to analyst estimates of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. Equities research analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).